RENNOVA HEALTH, INC. COMPLETES REVERSE STOCK SPLIT
Rennova Health, Inc. (OTC: RNVAD) announced a 1 for 10,000 reverse stock split, effective March 15, 2022. Following this action, the company's outstanding shares will decrease from approximately 44 billion to around 4.4 million. The split aims to consolidate shares without changing the par value of $0.0001. All outstanding preferred shares and stock options will also be adjusted accordingly. The reverse split was approved by directors on March 9, 2022, with majority shareholder consent received on December 15, 2021. The stock will trade under RNVAD for 20 days post-split.
- Reverse stock split reduces total outstanding shares from approximately 44 billion to 4.4 million, potentially improving share value.
- The reverse split could enhance the company's market perception and attract institutional investors.
- Significant decrease in share volume may raise concerns about market liquidity.
- The reverse stock split indicates potential financial distress, as such measures are often employed to comply with listing requirements.
WEST PALM BEACH, Fla., March 16, 2022 (GLOBE NEWSWIRE) -- Rennova Health, Inc. (OTC: RNVAD), today announced that effective at 5:00 pm, Eastern Time, on March 15, 2022 (the “Effective Time”), the Company completed a 1 for 10,000 reverse stock split of its outstanding common stock. The Company’s common stock will open for trading on Wednesday March 16, 2022, on a post-split basis and trade under the symbol RNVAD for 20 days.
As a result of the reverse stock split, every 10,000 shares of the Company’s common stock issued and outstanding on the Effective Time will be consolidated into one issued and outstanding share, except to the extent that the reverse stock split results in any of the Company’s stockholders owning a fractional share, which fractional share will be in that case paid in cash. In connection with the reverse stock split, there will be no change in the nominal par value per share of
Based on the number of shares outstanding on March 9, 2022, the reverse stock split will reduce the number of shares of the Company’s common stock outstanding from approximately 44 billion pre-reverse split shares to approximately 4.4 million post-reverse split.
All outstanding preferred shares, stock options, warrants, and equity incentive plans immediately prior to the reverse stock split generally will be appropriately adjusted by dividing the number of shares of common stock into which the preferred shares, stock options, warrants and equity incentive plans are exercisable or convertible by 10,000 and multiplying the exercise or conversion price by 10,000, as a result of the reverse stock split.
The Company has retained its transfer agent, Computershare, Inc., to act as its exchange agent for the reverse stock split. As necessary, Computershare will provide stockholders of record as of the Effective Time a letter of transmittal providing instructions for the exchange of their stock certificates. Stockholders owning shares via a broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to brokers’ particular processes, and will not be required to take any action in connection with the reverse stock split.
The reverse stock split was approved by the directors of the Company on March 9, 2022, pursuant to a resolution adopted by written consent of the holders of the majority of the total voting power of the Company’s securities on December 15, 2021.
About Rennova Health, Inc.
Rennova is a provider of health care services to rural communities. The Company owns one operating acute care hospital in Oneida, Tennessee known as Big South Fork Medical Center (classified as a critical access hospital), an acute care hospital and physician’s office located in Jamestown, Tennessee that it plans to reopen and operate, and a rural clinic in Kentucky. For more information, please visit www.rennovahealth.com
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Additional information concerning these and other risk factors are contained in the Company's most recent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.
Contact:
Rennova Health
561-855-1626
info@rennovahealth.com
FAQ
What is the purpose of Rennova Health's reverse stock split on March 15, 2022?
How will the reverse stock split affect my shares of RNVAD?
What happens to preferred shares and stock options after the reverse stock split?
When will Rennova Health's stock begin trading post-split?
